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Background: The standard therapy regimen of conventional osteosarcoma includes neoadjuvant chemotherapy
followed by surgical resection and postoperative chemotherapy. The percentage of necrotic tissue following
induction chemotherapy is assessed by using the Huvos grading system, which classifies patients as “poor
responders” (PR) and “good responders” (GR). The aim of this study was to identify molecular markers expressed
differentially between good and poor responders to neoadjuvant chemotherapy in order to predict the response to
chemotherapy in conventional osteosarcomas before beginning treatment.
Methods: Suppression Substractive Hybridization (SSH) was performed by using cDNA from frozen biopsy specimens.
Expression of selected relevant genes identified by SSH was validated by using QRT-PCR. Immunohistochemistry (IHC)
on tissue microarray (TMA) sections of 52 biopsies was performed to investigate protein expression in an independent
cohort.
Results: ERK1 and STAT3 mRNA level were significantly different between PR and GR in an independent cohort.
Phosphorylated STAT3 and ERK1 expressions by IHC on TMA were correlated with poor response to chemotherapy.
Conclusions: Our results suggest that ERK1 and STAT3 expression are good predictive markers for chemotherapy
response and that inhibitors might be used in combination with common chemotherapeutic drugs in conventional
osteosarcomas.
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Osteosarcoma, the most common type of primary bone
cancer, is a rare disease. Approximately 900 new cases of
osteosarcoma are diagnosed each year in the United
States (http://www.cancer.org/docroot/home/index.asp)
and 200 in France, including 150 in children (http://
www.fnclcc.fr/sor/SSP/CancersEnfant/PeauTissusSoutien/
Osteosarcome). Adjuvant and neoadjuvant chemother-
apy have significantly improved the long-term survival
rate for patients with osteosarcoma [1-3]. Nevertheless, re-
current disease still occurs in about 30–40% of patients* Correspondence: sebastien.salas@ap-hm.fr
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unless otherwise stated.and more than 70% of them die of their tumor, despite
second-line treatment. The standard therapy regimen of
high-grade osteosarcoma includes induction by multiagent
chemotherapy followed by surgical resection and postop-
erative chemotherapy [4]. The percentage of necrotic tis-
sue following induction chemotherapy is classified with
the Huvos grading system [5]. Patients with <90% tumor
necrosis following induction therapy are classified as
“poor responders” (PR) or Huvos grade I/II [6], while
more than 90% necrosis corresponds to Huvos grade III
and complete necrosis to Huvos grade IV. Good re-
sponders (GR) correspond to Huvos grade III/IV. The de-
gree of necrosis remains the only reliable prognostic factor
for the patients presenting with localized disease and is
used to guide the choice of postoperative chemotherapy.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,






Number of patients 5 4





Upper limb 2 1
Lower limb 3 3
Histological subtype
Osteoblastic 4 3
Osteoblastic and chondroblastic 1 1
Mean tumor size [95% IC] (cm) 12.5 [8-34] 9 [6.7-25]
Mean viable residual tumor cells [95% IC] (%) 2.5 [1-4.5] 25 [17-37]
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disease-free survival rate for poorly responding patients
with intensified postoperative therapy. No survival benefit
has been convincingly shown through the administration
of more intensified therapy to poor responders [3,7-10].
This suggests that there may be an innate biological differ-
ence between good responsive and poor responsive tu-
mors. Previous transcriptomic studies have shown that in
chemoresistant tumors, the genes involved in osteoclasto-
genesis, extracellular matrix remodeling, bone develop-
ment, tumor progression, drug resistance and angiogenesis
are up-regulated [11-17]. However, none of these molecu-
lar predictive factors can be used routinely. Therefore,
there is a need to establish reliable predictive biomarkers
for the response to chemotherapy at the time of diagnosis.
The aim of this study was to identify molecular markers
expressed differentially between “good” and “poor” re-
sponders to neoadjuvant chemotherapy in order to predict
the response to chemotherapy in conventional osteosar-
coma before beginning treatment, and to elucidate the
mechanisms involved in this response. We identified sev-
eral subsets of novel potential candidate genes. In particu-
lar, our data suggest that ERK1 and STAT3 expression are
involved in the response to chemotherapy and that they
could be therapeutic targets.
Methods
Patients and tumor specimens
The response to preoperative chemotherapy was assessed
on resected specimens according to Rosen’s protocol [4].
To identify differentially expressed genes between “good”
and “poor” responders (GR and PR) to chemotherapy,
Suppression Subtractive Hybridization (SSH) was per-
formed by using cDNA from frozen biopsy specimens
taken for diagnosis prior to treatment. SSH was performed
by using 5 samples of GR patients (three males and two
females, mean age 14 years) and 4 samples of PR patients
(two males and two females, mean age 13.5 years). All
patients received preoperative and postoperative chemo-
therapy derived from the SFOP OS 94 regimen [18]. Clini-
copathological characteristics of the patients studied by
SSH are presented in Table 1. The two groups were simi-
lar in tumor volume, tumor location and histological sub-
type. Expression of selected relevant genes identified by
SSH was validated by using real-time quantitative RT-PCR
(QRT-PCR). For QRT-PCR, the same specimens and add-
itional specimens of 22 patients were obtained. The whole
cohort consisted of 13 GR and 18 PR. Immunohisto-
chemistry (IHC) was performed on Tissue Microarray
(TMA) sections consisting of 52 biopsies of patients with
a conventional osteosarcoma. Six of 9 samples used for
SSH were used for TMA. 18 of the 31 samples used in
QRT-PCR were used for TMA. In total, among the 52 pa-
tients in the TMA validation cohort, only 5 receivedchemotherapy without high-dose MTX. The vast majority
of patients (40) were those treated according to protocol
OS94 or by neoadjuvant chemotherapy with methotrex-
ate, vepeside and ifosfamide. All samples were obtained
after informed consent from patients or their parents
when the patients were under the age of 18.
Research involving the patients have been performed
with the approval of Protection of the Person Center: CPP
sud Méditerranée 1 ethics committee (authorization num-
ber: DC-2008-309) in compliance with the Helsinki Dec-
laration. Samples were from a tumor bank that respects
the ethical charter of the French National Cancer Institute
(AP-HM Biobank authorization number 2013-1786).RNA preparation
Total RNA extraction was performed from frozen tumor
specimens by using the acid guanidinium isothiocyanate/
phenol/chloroform procedure. Before use, RNA samples
were treated with 10U ribonuclease-free deoxyribonucle-
ase (Promega, France) at 37°C for 15 min. Tests for purity
and quality were performed on a nanodrop spectropho-
tometer and the Agilent 2100 Bioanalyser RNA LabChip
kit (Agilent Technologies, Palo Alto, CA, USA) [19,20].
Only samples with RNA integrity Number (RIN) > 7 and
no evidence of ribosomal degradation were included.SMART-Suppression Subtractive Hybridization (SMART:
“switching mechanism at 5’ end of the RNA transcript”)
Poly(A) +mRNA were isolated from GR and PR total
RNA using an Oligotex mRNA isolation kit (Qiagen,
France) and gene expression between these two mRNA
populations was compared by SMART-SSH using a Super
PCR cDNA Synthesis Kit for cDNA synthesis (Clontech)
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principle previously described by Diatchenko et al. [21].
Cloning and analysis of subtracted clones
Products from the final PCR amplification were cloned
into a Topo TA cloning vector (Invitrogen Life Tech-
nologies, France) and electro-transferred into One Shot
E. coli. Differential screening was performed to eliminate
false positives. Hybridizations were performed in dupli-
cate according to standard procedures. Specific clones
were prepared by using a Qiagen plasmid mini-kit and
sequenced (QIAGEN France SAS, Coutaboeuf, France).
Nucleic acid homology searches were carried out with
the BLAST program at the NCBI, USA.
Quantitative Reverse Transcription Polymerase Chain
Reaction (QRT-PCR)
QRT-PCR was used to accurately detect the changes of
expression of selected relevant genes: ERK1 and STAT3
gene expression levels and ribosomal 18S RNA as refer-
ence sequence. Total RNA (1 μg) DNA-free was reverse-
transcribed into cDNA using hexamers (Pharmacia
Biotech, Orsay, France) and Superscript II Reverse Tran-
scriptase (Invitrogen Life Technologies, France). Genes
of interest and 18S rRNA were amplified, detected and
quantified in real-time by using the Light Cycler Real-
Time PCR (Roche Applied Science, Meylan, France).
QRT-PCR was performed by using the oligonucleotides
and sequence parameters described in Table 2 in a
medium containing 1X LightCycler 480 SYBR Green I
master mix, 0.25 μM of each primer and 20 ng of cDNA.
Each PCR reaction was preceded by one activation cycle of
95°C for 5 min and ended by establishing a melting curve
5 degrees above the oligonucleotide melting temperature.
Immunohistochemistry (IHC) on tissue microarray
sections (TMA)
Automated immunohistochemistry was performed on
slides of TMA paraffin blocks. The 52 tumor specimens
were all fixed in 4% formalin. Fleshy tissue was separated
from calcified areas to avoid unnecessary decalcification.
When necessary, tumor specimens were decalcified in a
solution of 22% formic acid. TMA were prepared as previ-
ously described [20]. For each sample, three representativeTable 2 Description of oligonucleotides and sequence param
Name gene Oligo direct Oligo reverse
18S CTACCACATCCAAGGAAGGCA TTTTTCGTCACTACCTCC
ERK1 CTAAAGCCCTCCAACCTGCT CAGCCCACAGACCAGA
STAT3 AAAGTCAGGTTGCTGGTCAAA TGCCGTTGTTGGATTCTTsample areas were carefully selected from a hematoxylin–
eosin-stained section of a donor block. Core cylinders
with a diameter of 1 mm each were punched from three
representative areas and deposited onto two separate re-
cipient paraffin blocks by using a specific arraying device
(Alphelys). To determine the expression of activated forms
of STAT3 and ERK1 proteins, we used anti-phospho-
STAT3 (Tyr705) (polyclonal, 9131 from Cell Signaling
Technology, dilution 1/20) and anti-phospho-ERK1 (poly-
clonal, clone 20G11 from Cell Signaling Technology, dilu-
tion: 1/100) antibodies. Automated IHC was performed
with a Ventana automate (Benchmark XT, Ventana Med-
ical Systems SA, Illkirch, France). Positive external control
was a glioblastoma for both pSTAT3 and pERK1. Negative
controls were also included and corresponded to omission
of primary antibody or irrelevant antibodies of the same
isotype. IHC was scored positive when nuclear staining
was observed. A semi-quantitative analysis was done for
positive specimens without knowledge of clinical data.
Percentage of stained cells and staining intensity (weak,
moderate, high) were taken into account to obtain the
score. Score 0 was attributed to tumors with absence of
staining. Score 1 was attributed to tumors with low inten-
sity of staining whatever the number of stained nuclei or to
tumors with no more than 25% of nuclei immunostained
with moderate intensity. Score 2 corresponded to stained
nuclei numbering between 25% and 50% with moderate in-
tensity or to fewer than 25% of stained nuclei with high in-
tensity. Score 3 was defined as either more than 50% of
stained nuclei with moderate intensity or more than 25%
of stained nuclei with high staining intensity. A mean score
was proposed for the three areas of each tumor. Three in-
dependent observers evaluated the IHC results blind to
clinical data. A consensus score was reached and statistical
analysis was performed from the consensus score.
Data analysis
Relationships between response to chemotherapy (GR
vs. PR) and other parameters used were obtained by
using non-parametric tests, the Fisher exact test and the
Mann-Whitney test when qualitative and continuous re-
spectively. All tests were two-sided. P-value was consid-
ered significant when ≤ 5%. SAS System version 9.2 (SAS
Institute Inc., Cary, NC) and Stata software (version 10.1eters for QRT-PCR
PCR conditions Cycle number GeneInfo identifier
CCG 95°C 15 sec 35 124517659
67°C 30 sec
TGT 95°C 15 sec 45 158138506
60°C 30 sec
C 95°C 15 sec 45 76253927
60°C 30 sec
Salas et al. BMC Cancer 2014, 14:606 Page 4 of 11
http://www.biomedcentral.com/1471-2407/14/606Special Edition, StataCorp, College Station, Texas) were
used to perform data analyses.
Results
Patients
Clinicopathological characteristics of the patients studied
are presented in Table 3.
Identification of differentially expressed genes by SSH in PR
A subtractive cDNA library of PR was generated. 126 se-
lected clones were sequenced (Table 4). The following
genes were selected on the basis of their known roles
in tumorigenesis or chemoresistance: ACTN1, AKT2,
ANXA2, CADM1, CDKN2C(P18), FN1, GAL1, HRAS,
IGFBP3, LMNA, ERK1 and STAT3. Particularly, STAT3
is a key factor for chemosensitivity in human epithe-
lial ovarian cancer cells and thyroid cancer-derived
CD133+ cells [22-24]. Recent studies show that ERKs
may also be activated in response to chemotherapeutic
drugs, and pERK1/2 played critical roles in drug re-
sistance [25-28]. Thus, these selected genes were
tested by QRT-PCR.
QRT-PCR validation of selected genes expressed in PR
versus GR by SSH
Only STAT3 mRNA level and ERK1 mRNA level were sig-
nificantly different between PR and GR. Quantification ofTable 3 Clinicopathological characteristics of the 52




Number of patients 52
Age
Mean age at diagnosis [95% IC]a (years) 17.4 [5;80]
Sex
Male (%) 34 (65.4)




Histological diagnosis and subtype
High-grade osteosarcomas of central “conventional” type 52
Osteoblastic (%) 38 (73)
Chondroblastic (%) 5 (9.5)
Telangiectasic (%) 3 (6)
Fibroblastic (%) 2 (4)
Mixed subtypeb (%) 4 (7.5)
aConfidence Interval, for the whole cohort, to ascertain that the screening
cohort is a representative subset of the whole.
bOsteoblastic and chondroblastic or fibroblastic.STAT3 and ERK1 mRNA transcripts revealed higher
mRNA levels in PR compared to GR samples (p = 0.019
and p = 0.046 respectively). The mean level of STAT3
mRNA was 0.820 [0.280-13.970] in PR versus 0.310
[0.230-2.370] in GR samples (Figure 1A) and the mean
level of ERK1 was 0.270 [0.110-4.340] in PR versus 0.150
[0.088-0.710] in GR samples (Figure 1B).
Validation at protein level using immunohistochemistry
for pSTAT3 and pERK1 (Tables 5 and 6)
pSTAT3 nuclear expression was examined in 45 cases
out of 52 and a high score was observed in 20 cases
(score 2 and 3). pERK1 expression was examined in 45
cases out of 52 (low score in 25 cases and high score in
20 cases) (Figure 2). pSTAT3 protein expression was
correlated to poor response to chemotherapy for a per-
centage of viable residual cells ≤10%, with the higher
scores in the PR group (p = 0.036). A statistically signifi-
cant correlation was also found between pERK1 protein
expression and response to chemotherapy when compar-
ing low scores (0-1) versus high scores (2-3) (p = 0.007).
Moreover, the correlation between the expression of
pSTAT3 and pERK1 in IHC and the response to chemo-
therapy remained statistically significant for patients
under 25 years (p = 0.024 and p = 0.010 respectively). For
a percentage of viable residual cells lower than 5%, a sta-
tistically significant correlation was still found between
pSTAT3 or pERK1 protein expression and response to
chemotherapy (p = 0.013 and p = 0.035 respectively).
Whatever the threshold (5 or 10%), positive predictive
value (probability of belonging to the group of PR in
case of high score) of both pSTAT3 and pERK1 in com-
bination was 91%. Negative predictive value (probability
of belonging to the group of GR in case of low score) of
both pSTAT3 and pERK1 in combination for a 5 and
10% threshold were 69% and 75% respectively
Discussion
SSH is a molecular biology technique that enables the
identification of differentially expressed genes between
two groups with high sensitivity. By comparing PR to
GR prior to chemotherapy among patients with an
osteosarcoma, we found 126 clones. ERK1 and STAT3,
the genes selected on the basis of their roles in tumori-
genesis or chemoresistance, were further studied by
QRT-PCR in an independent cohort. ERK1 and STAT3
expressions assessed by QRT-PCR and IHC were signifi-
cantly linked to the response to chemotherapy. The pro-
tein encoded by ERK1 is a member of the MAP kinase
family and acts in a signalling cascade that regulates
various cellular processes such as proliferation, differen-
tiation, and cell cycle progression in response to a var-
iety of extracellular signals. We found ERK1/2 positivity
score by IHC and ERK1/2 IHC high score (score 2 and 3)
Table 4 Identification of genes differentially expressed by SSH in PR
Gene title Gene symbol Chromosomal location
Actin, alpha 1, skeletal muscle ACTA1 chr1q42.13-q42.2
Actin, beta ACTB chr7p15-p12
Actin, gamma 1 ACTG1 chr17q25
Actinin, alpha 1 ACTN1 chr14q24.1-q24.2|14q24|
14q22-q24
ADAM metallopeptidase with thrombospondin type 1 motif, 20 ADAMTS20 chr12q12
v-akt murine thymoma viral oncogene homolog 2 AKT2 chr19q13.1-q13.2
Ankyrin repeat domain 11 ANKRD11 chr16q24.3
Annexin A2 ANXA2 chr15q21-q22
AT rich interactive domain 4B (RBP1-like) ARID4B chr1q42.1-q43
Actin-related protein 2/3 complex, subunit 2, 34 kDa ARPC2 chr2q36.1
ATPase family, AAA domain containing 3A ATAD3A chr1p36.33
ATP synthase, H + transporting, mitochondrial F0 complex, subunit
E///major facilitator superfamily domain containing 7
ATP5I///MFSD7 chr4p16.3
Bromo adjacent homology domain containing 1 BAHD1 chr15q15.1
Breast carcinoma amplified sequence 3 BCAS3 chr17q23
Branched chain aminotransferase 2, mitochondrial BCAT2 chr19q13
Chromosome 14 open reading frame 112 C14orf112 chr14q24.2
Chromosome 14 open reading frame 2 C14orf2 chr14q32.33
Chromosome 20 open reading frame 194 C20orf194 chr20p13
Cell adhesion molecule 1 CADM1 chr11q23.2
Coiled-coil domain containing 28B CCDC28B chr1p35.1
Chaperonin containing TCP1, subunit 8 (theta) CCT8 chr21q22.11
Cell division cycle 34 homolog (S. cerevisiae) CDC34 chr19p13.3
Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) CDKN2C chr1p32
Carbohydrate (chondroitin 4) sulfotransferase 11 CHST11 chr12q
Creatine kinase, brain CKB chr14q32
CDC28 protein kinase regulatory subunit 1B CKS1B chr1q21.2
CLPTM1-like CLPTM1L chr5pter-p15.3
Cornifelin CNFN chr19q13.2
Collagen, type V, alpha 1 COL5A1 chr9q34.2-q34.3
Catechol-O-methyltransferase COMT chr22q11.21-q11.23|22q11.21
Cytochrome c oxidase subunit VIa polypeptide 1 COX6A1 chr12q24.2|12q24.2
Cytokine receptor-like factor 1 CRLF1 chr19p12
Chondroitin sulfate glucuronyltransferase CSGlcA-T chr7q36.1
Casein kinase 2, alpha prime polypeptide CSNK2A2 chr16q21
cutA divalent cation tolerance homolog (E. coli) CUTA chr6pter-p21.31
dodecenoyl-Coenzyme A delta isomerase
(3,2 trans-enoyl-Coenzyme A isomerase)
DCI chr16p13.3
Dicarbonyl/L-xylulose reductase DCXR chr17q25.3
DEAD (Asp-Glu-Ala-As) box polypeptide 19A DDX19A chr16q22.1
DEAD (Asp-Glu-Ala-As) box polypeptide 19B///DEAD (Asp-Glu-Ala-As)
box polypeptide 19A
DDX19A///DDX19B chr16q22.1
DEAD (Asp-Glu-Ala-Asp) box polypeptide 39 DDX39 chr19p13.12
Eukaryotic translation elongation factor 1 delta
(guanine nucleotide exchange protein)
EEF1D chr8q24.3
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Table 4 Identification of genes differentially expressed by SSH in PR (Continued)
Eukaryotic elongation factor-2 kinase EEF2K chr16p12.1
Eukaryotic translation initiation factor 3, subunit H EIF3H chr8q24.11
Eukaryotic translation initiation factor 4 gamma, 3 EIF4G3 chr1p36.12
Fas apoptotic inhibitory molecule 3 FAIM3 chr1q32.1
FK506 binding protein 7 FKBP7 chr2q31.2
Kappa-actin FKSG30 chr2q21.1
Flavin containing monooxygenase 5 FMO5 chr1q21.1
Fibronectin 1 FN1 chr2q34
FERM domain containing 5 FRMD5 chr15q15.3
Golgi SNAP receptor complex member 2 GOSR2 chr17q21
Glypican 1 GPC1 chr2q35-q37
G protein-coupled receptor 108 GPR108 chr19p13.3






v-Ha-ras Harvey rat sarcoma viral oncogene homolog HRAS chr11p15.5
Heparan sulfate proteoglycan 2 HSPG2 chr1p36.1-p34
Insulin-like growth factor 2 mRNA binding protein 3 IGF2BP3 chr7p11
Inositol(myo)-1(or 4)-monophosphatase 2 IMPA2 chr18p11.2
Integrator complex subunit 1 INTS1 chr7p22.3
Importin 11 IPO11 chr5q12.1
Jumonji domain containing 2C JMJD2C chr9p24.1
KIAA0999 protein KIAA0999 chr11q23.3
Laminin, alpha 4 LAMA4 chr6q21
Lectin, galactoside-binding, soluble, 1 (galectin 1) LGALS1 chr22q13.1
Lamin A/C LMNA chr1q21.2-q21.3
Ribosomal protein S16///similar to 40S ribosomal protein S16 LOC441876///RPS16 chr19q13.1///chr1p36.21
Leucine-rich repeat containing 28 LRRC28 chr15q26.3
Microtubule-associated protein 1S MAP1S chr19p13.11
Mitogen-activated protein kinase 3 MAPK3 (ERK1) chr16p11.2
Major facilitator superfamily domain containing 5 MFSD5 chr12q13.13
Mitochondrial ribosomal protein S7 MRPS7 chr17q25
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9 kDa NDUFA4 chr7p21.3
NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20 kDa
(NADH-coenzyme Q reductase)
NDUFS7 chr19p13.3
NADH dehydrogenase (ubiquinone) flavoprotein 1, 51 kDa NDUFV1 chr11q13
Nuclear factor I/C (CCAAT-binding transcription factor) NFIC chr19p13.3
NOL1/NOP2/Sun domain family, member 5 NSUN5 chr7q11.23
NOL1/NOP2/Sun domain family, member 5B NSUN5B chr7q11.23
NOL1/NOP2/Sun domain family, member 5C NSUN5C chr7q11.23
Nucleoporin 214 kDa NUP214 chr9q34.1
Nucleoporin 85 kDa NUP85 chr17q25.1
PDZ domain containing 2 PDZD2 chr5p13.3
Periplakin PPL chr16p13.3
Protein phosphatase 1, regulatory (inhibitor) subunit 12B PPP1R12B chr1q32.1
Protein phosphatase 2 (formerly 2A), regulatory subunit A, alpha isoform PPP2R1A chr19q13.33
Protein kinase C substrate 80 K-H PRKCSH chr19p13.2
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Table 4 Identification of genes differentially expressed by SSH in PR (Continued)
Protein arginine methyltransferase 2 PRMT2 chr21q22.3
RNA binding protein, autoantigenic (hnRNP-associated with lethal
yellow homolog (mouse))
RALY chr20q11.21-q11.23
RNA binding motif protein 4 RBM4 chr11q13
RNA binding motif protein 4B RBM4B chr11q13
RNA binding motif protein 8A RBM8A chr1q12
Ribosomal protein L13 RPL13 chr16q24.3|17p11.2
Ribosomal protein L13a RPL13A chr19q13.3
Ribosomal protein L19 RPL19 chr17q11.2-q12
Ribosomal protein L23a RPL23A chr17q11
Ribosomal protein L31 RPL31 chr2q11.2
Ribosomal protein, large, P1 RPLP1 chr15q22
Ribosomal protein S12 RPS12 chr6q23.2
Ribosomal protein S14 RPS14 chr5q31-q33
Ribosomal protein S17 RPS17 chr15q
Ribosomal protein S21 RPS21 chr20q13.3
Ribosomal protein S27 (metallopanstimulin 1) RPS27 chr1q21
Ribosomal protein S6 RPS6 chr9p21
RNA pseudouridylate synthase domain containing 4 RPUSD4 chr11q24.2
Ribosomal RNA processing 1 homolog B (S. cerevisiae) RRP1B chr21q22.3
Retinoid X receptor, alpha RXRA chr9q34.3
Synaptonemal complex protein SC65 SC65 chr17q21.2
Splicing factor, arginine/serine-rich 3 SFRS3 chr6p21
Serine hydroxymethyltransferase 2 (mitochondrial) SHMT2 chr12q12-q14
SIVA1, apoptosis-inducing factor SIVA1 chr14q32.33
SIVA1, apoptosis-inducing factor SIVA1 chr14q32.33
Solute carrier family 16, member 8 (monocarboxylic acid transporter 3) SLC16A8 chr22q12.3-q13.2
Solute carrier family 20 (phosphate transporter), member 2 SLC20A2 chr8p12-p11
Small nuclear ribonucleoprotein D3 polypeptide 18 kDa SNRPD3 chr22q11.23
Signal transducer and activator of transcription 3
(acute-phase response factor)
STAT3 chr17q21.31
Serine/threonine kinase 24 (STE20 homolog, yeast) STK24 chr13q31.2-q32.3
T-cell, immune regulator 1, ATPase, H + transporting,
lysosomal V0 subunit A3
TCIRG1 chr11q13.2
Testis-specific kinase 1 TESK1 chr9p13
Thymosin, beta 10 TMSB10 chr2p11.2
Transportin 3 TNPO3 chr7q32.1
Tetraspanin 9 TSPAN9 chr12p13.33-p13.32
Ubiquitin A-52 residue ribosomal protein fusion product 1 UBA52 chr19p13.1-p12
Vacuolar protein sorting 28 homolog (S. cerevisiae) VPS28 chr8q24.3
Williams-Beuren syndrome chromosome region 16 WBSCR16 chr7q11.23
WW domain containing oxidoreductase WWOX chr16q23.3-q24.1
X antigen family, member 1D///X antigen family,
member 1C///X antigen family, member 1E///X antigen family,




Zinc finger protein 449 ZNF449 chrXq26.3
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Figure 1 RTQ-PCR analysis of STAT3 and ERK1 genes. A: Quantification of STAT3 mRNA with 18S rRNA reference gene transcript confirmed
higher STAT3 mRNA levels in poor responder (PR) samples compared with good responder (GR) samples (p = 0.019). B: Quantification of MAPK3
(ERK1) mRNA with 18S rRNA reference gene transcript confirmed higher MAPK3 (ERK1) mRNA levels in PR samples compared with GR samples
(p = 0.046).
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suggested that ERK1/2 pathway could be involved in
osteosarcoma as it has supported by Pignochino et al.
study that showed activated ERK 1/2 pathway in 66.6% of
osteosarcoma samples. Moreover, the same team also
showed that Sorafenib, a tyrosine kinase inhibitor, blocks
tumor growth, angiogenesis and metastatic potential in
preclinical models of osteosarcoma through a mechanism
potentially involving the inhibition of ERK1/2 [29]. No at-
tempt to investigate the link between ERK1 expression
and response to chemotherapy was made in vivo. How-
ever, our work suggested that ERK1 could be involved in
drug resistance as reported recently by Si et al. with an
approach by RNAi-mediated knockdown of ERK1/2 inhi-
biting cell proliferation and invasion and increasing che-
mosensitivity to cisplatin in human osteosarcoma U2-OS
cells in vitro [30].Table 5 Correlation between phosphorylated STAT3 and ERK
percentage of viable residual cells ≤10%
IHC score G
Phosphorylated STAT3 0 or 1 1
2 or 3 6
VPP(PR) = 14/20 = 70%/VPN(GR) = 16/25 = 64%
Phosphorylated ERK1 0 or 1 1
2 or 3 5
VPP(PR) = 15/20 = 75%/VPN(GR) = 17/25 = 68%
Phosphorylated STAT3 and ERK1 Both 0-1 1
Intermediate 8
Both 2-3 1
VPP(both/PR) = 10/11 = 91%/VPN(both/GR) = 12/16 = 75%STAT3 is one of the transcription factors reported to
play an important role in tumor survival, proliferation,
angiogenesis and metastasis. In normal cells, STAT3 is
activated transiently to maintain homeostasis. However,
if STAT3 continues to be activated, the abnormal level of
expression can trigger oncogenic pathways. Aberrant ac-
tive STAT3 promotes uncontrolled growth and survival
through dysregulation of expression of downstream tar-
geted genes including survivin, Bcl-xL, Bcl-2, Mcl-1,
c-Myc and cyclin D1. Constitutive activation of the
STAT3 pathway has recently been shown in several ma-
lignancies, especially osteosarcoma [31]. It has recently
been implicated in resistance to chemotherapy-induced
apoptosis [32]. Furthermore, activation of STAT3 in sev-
eral cancers has been found to be correlated with clinical
outcome especially in osteosarcoma. A high level of ex-
pression of STAT3 by IHC in 76 biopsies of patients1 IHC expression to poor response to chemotherapy for a








Table 6 Correlation between phosphorylated STAT3 and ERK1 IHC expression to poor response to chemotherapy for a
percentage of viable residual cells lower than 5%
IHC score Good responders Poor responders p-value
Phosphorylated STAT3 0 or 1 13 12 0.013
2 or 3 3 17
VPP(PR) = 17/20 = 85%/VPN(GR) = 13/25 = 52%
Phosphorylated ERK1 0 or 1 13 12 0.035
2 or 3 4 16
VPP(PR) = 16/20 = 80%/VPN(GR) = 13/25 = 52%
Phosphorylated STAT3 and ERK1 Both 0-1 11 5 0.007
Intermediate 5 10
Both 2-3 1 10
VPP(both/PR) = 10/11 = 91%/VPN(both/GR) = 11/16 = 69%
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http://www.biomedcentral.com/1471-2407/14/606with an osteosarcoma was a poor prognostic factor for
both overall survival and disease-free survival in univari-
ate and multivariate analysis [33]. High staining with
pSTAT3 was also of prognostic value in another series of
51 conventional osteosarcomas [34]. In addition, inhib-
ition of STAT3 plays a role in proliferation, apoptosis and
migration in osteosarcoma cells in vitro. The down-
regulation of STAT3 by miR-125b suppresses in vitro pro-
liferation and migration of osteosarcoma cells [35]. STAT3
inhibition by RNA interference induces inhibition ofscore 0 
score 2 
Figure 2 IHC pSTAT3 scores. Score 0: negative staining (X200). Score 1: >
<50% cells with moderate staining intensity and <25% of cells are highly s
moderate staining intensity (X200).proliferation and apoptosis enhancement in osteosarcoma
cells [33]. The novel curcumin analog FLLL32 decreases
STAT3 DNA binding activity and expression, and induces
apoptosis in osteosarcoma cell lines [36]. The small mole-
cules, LLL12 and FLLL32, inhibit STAT3 phosphorylation
and exhibit potent growth suppressive activity in osteosar-
coma cells and tumor growth in mice [37]. In contrast,
oncostatin M promotes STAT3 activation, VEGF produc-
tion, and invasion in osteosarcoma cell lines [38]. Finally,
STAT3 is involved in drug resistance in osteosarcoma cellscore 1 
score 3 
50% of nuclei are labeled with low staining intensity (X200). Score 2:
tained (X200). Score 3: more than 50% of nuclei are stained with
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http://www.biomedcentral.com/1471-2407/14/606lines. Ryu et al. recently showed that the STAT3 pathway
was overexpressed in MDR osteosarcoma cells and that
inhibitors of STAT3 such as CDDO-Me could reduce re-
sistance to doxorubicin in these cell lines [31]. In our
study, we have showed an expression of pSTAT3 in 58%
of cases. This activated STAT3 pathway was correlated to
poor response to chemotherapy. Thus, our results are
consistent with the results of the literature in vitro
through the analysis of patient samples.
The effects of EGFR are mediated by activation of
downstream signal transduction cascades that include
Janus tyrosine kinases (Jak), Signal Transducers and Ac-
tivators of Transcription (STAT), Phophatidyl Inositol 3
Kinase (PI3K)/Akt and Ras/RAf/MAP kinase (ERK). The
prognostic value of EGFR and its downstream signaling
molecules such as STAT3 and ERK1 have been studied
in many tumor types. Only one study [39] simultan-
eously examined the status of EGFR and four down-
stream molecules - pSTAT3, pERK1, pAkt, survivin - by
IHC in 47 samples of conventional osteosarcomas. ERK1
and survivin expression were statistically correlated with
survival. A high expression was negatively correlated
with prognosis. Furthermore, EGFR expression was cor-
related with expression of ERK1 and it was observed a
significant association of survivin expression with STAT3
and ERK activation. These results and ours support the
idea that ERK is a downstream signaling molecule of
EGFR and also suggest a link between the EGFR signal-
ing pathway and drug resistance through ERK1 and
STAT3 expression in conventional osteosarcoma.Conclusions
We have shown that high pSTAT3 and pERK1 expres-
sion in the biopsies are suggestive of poor response to
chemotherapy. The elevated positive predictive value of
high score of both pSTAT3 and pERK1 in combination
(91%) highly suggests that IHC test could be used at the
time of diagnosis to stratifying patients enrolled in ran-
domized trials. Our results also suggest that STAT3 and
ERK1 inhibitors might be used in combination with
common chemotherapeutic drugs in osteosarcoma in
order to increase the response to chemotherapy and to
improve the prognosis. Finally, other genes identified by
SSH remain to be explored and a prospective validation
phase on a larger cohort is still needed before these bio-
markers could be used in clinical practice.
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